TransMedics Group (NASDAQ:TMDX) Earns Hold Rating from Needham & Company LLC

Needham & Company LLC reissued their hold rating on shares of TransMedics Group (NASDAQ:TMDX) in a research note published on Wednesday,Benzinga reports.

A number of other analysts have also recently commented on the stock. Robert W. Baird reduced their target price on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. Canaccord Genuity Group reissued a “buy” rating and set a $104.00 price objective on shares of TransMedics Group in a research report on Tuesday, March 11th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $75.00 target price (down from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Piper Sandler lowered their target price on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 11th. Finally, Oppenheimer restated an “outperform” rating and issued a $125.00 price target on shares of TransMedics Group in a research report on Tuesday, December 3rd. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $122.70.

TransMedics Group Price Performance

Shares of TMDX opened at $68.58 on Wednesday. The firm has a fifty day simple moving average of $69.11 and a two-hundred day simple moving average of $88.41. The firm has a market cap of $2.31 billion, a PE ratio of 72.96 and a beta of 2.12. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. TransMedics Group has a 1-year low of $55.00 and a 1-year high of $177.37.

Hedge Funds Weigh In On TransMedics Group

Several hedge funds have recently modified their holdings of the stock. Atlas Capital Advisors Inc. purchased a new stake in shares of TransMedics Group in the fourth quarter worth about $31,000. Hager Investment Management Services LLC purchased a new stake in shares of TransMedics Group during the 4th quarter worth approximately $33,000. Sachetta LLC purchased a new stake in shares of TransMedics Group during the 4th quarter worth approximately $40,000. AlphaQuest LLC bought a new position in shares of TransMedics Group during the 4th quarter valued at approximately $52,000. Finally, Quarry LP grew its holdings in shares of TransMedics Group by 557.1% in the third quarter. Quarry LP now owns 368 shares of the company’s stock valued at $58,000 after purchasing an additional 312 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.